FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016971021> ?p ?o ?g. }

• W2016971021 endingPage "154" @default.
• W2016971021 startingPage "147" @default.
• W2016971021 abstract "Chronic (1-Year) Safety Evaluation of Ipazilide Fumarate, an Antiarrhythmic Agent, Administered Orally to Rats. Greener, Y., Barbolt, T. A., Zelinger, D. J., and Gossett, K. A. (1993). Fundam. Appl. Toxicol. 20, 147-154. Ipazilide fumarate (WIN 54177-4) is a chemically novel anti-arrhythmic agent that prolongs ventricular refractoriness and possesses antiectopic activity. The compound is being developed as oral and iv therapy for ventricular and supraventricular arrhythmias. Since ipazilide therapy may require long-term use, a 1-year oral gavage study (daily dosages of 20, 80, or 160 mg/kg) was conducted in rats. Controls received the purified water vehicle. Treatment-related clinical signs were limited to postdosing salivation. Increased relative liver weight (females, at 80 and 160 mg/kg) was correlated with centrilobular hypertrophy, but was not associated with significant increased serum liver enzymes activities. These liver weight changes were interpreted as an adaptive metabolic response and were not considered toxicologically significant. An increased incidence of centrilobular hepatocellular vacuolation representing lipid accumulation over that observed for male controls occurred for males in all ipazilide-treated groups. This observation, however, was not correlated with elevated hepatic enzyme activities. Hepatocellular basophilic foci were observed for females only (80 and 160 mg/kg groups); however, the significance of this lesion is unclear. Transient dosage-related duodenal villous atrophy/sloughing was observed for males from the 80 and 160 mg/kg groups. Mild increases in hemoglobin, hematocrit, urea, and creatinine (160 mg/kg), attributed to treatment, were considered of minor toxicologic importance. Likewise, no clinical or anatomical pathologic observations that may indicate cardiac toxicity were determined. It is concluded that a dosage of 20 mg/kg (two to three times the clinical efficacious dosage) was considered a no-effect dosage level since it did not produce any effects of toxicological significance." @default.
• W2016971021 created "2016-06-24" @default.
• W2016971021 creator A5009358764 @default.
• W2016971021 creator A5030341537 @default.
• W2016971021 creator A5046442782 @default.
• W2016971021 creator A5054703017 @default.
• W2016971021 date "1993-02-01" @default.
• W2016971021 modified "2023-09-25" @default.
• W2016971021 title "Chronic (1-Year) Safety Evaluation of Ipazilide Fumarate, an Antiarrhythmic Agent, Administered Orally to Rats" @default.
• W2016971021 doi "https://doi.org/10.1006/faat.1993.1020" @default.
• W2016971021 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8449385" @default.
• W2016971021 hasPublicationYear "1993" @default.
• W2016971021 type Work @default.
• W2016971021 sameAs 2016971021 @default.
• W2016971021 citedByCount "0" @default.
• W2016971021 crossrefType "journal-article" @default.
• W2016971021 hasAuthorship W2016971021A5009358764 @default.
• W2016971021 hasAuthorship W2016971021A5030341537 @default.
• W2016971021 hasAuthorship W2016971021A5046442782 @default.
• W2016971021 hasAuthorship W2016971021A5054703017 @default.
• W2016971021 hasConcept C126322002 @default.
• W2016971021 hasConcept C134018914 @default.
• W2016971021 hasConcept C162156334 @default.
• W2016971021 hasConcept C197934379 @default.
• W2016971021 hasConcept C2777056448 @default.
• W2016971021 hasConcept C2780306776 @default.
• W2016971021 hasConcept C2780959883 @default.
• W2016971021 hasConcept C71924100 @default.
• W2016971021 hasConcept C90924648 @default.
• W2016971021 hasConcept C98274493 @default.
• W2016971021 hasConceptScore W2016971021C126322002 @default.
• W2016971021 hasConceptScore W2016971021C134018914 @default.
• W2016971021 hasConceptScore W2016971021C162156334 @default.
• W2016971021 hasConceptScore W2016971021C197934379 @default.
• W2016971021 hasConceptScore W2016971021C2777056448 @default.
• W2016971021 hasConceptScore W2016971021C2780306776 @default.
• W2016971021 hasConceptScore W2016971021C2780959883 @default.
• W2016971021 hasConceptScore W2016971021C71924100 @default.
• W2016971021 hasConceptScore W2016971021C90924648 @default.
• W2016971021 hasConceptScore W2016971021C98274493 @default.
• W2016971021 hasIssue "2" @default.
• W2016971021 hasLocation W20169710211 @default.
• W2016971021 hasLocation W20169710212 @default.
• W2016971021 hasOpenAccess W2016971021 @default.
• W2016971021 hasPrimaryLocation W20169710211 @default.
• W2016971021 hasRelatedWork W1966504330 @default.
• W2016971021 hasRelatedWork W1974041167 @default.
• W2016971021 hasRelatedWork W1979139803 @default.
• W2016971021 hasRelatedWork W2037631372 @default.
• W2016971021 hasRelatedWork W2087199815 @default.
• W2016971021 hasRelatedWork W2184613897 @default.
• W2016971021 hasRelatedWork W2387998278 @default.
• W2016971021 hasRelatedWork W2389506545 @default.
• W2016971021 hasRelatedWork W2748952813 @default.
• W2016971021 hasRelatedWork W3153485154 @default.
• W2016971021 hasVolume "20" @default.
• W2016971021 isParatext "false" @default.
• W2016971021 isRetracted "false" @default.
• W2016971021 magId "2016971021" @default.
• W2016971021 workType "article" @default.